ALGIERS - The public pharmaceutical group Saidal signed a memorandum of understanding (MoU) with the Swiss group "Bioexpress Therapeutics," with a view to establishing a framework for cooperation in the fields of biotechnology, training, and skills development, according to a communiqué issued by the group on Monday.

The memorandum was signed on Sunday in Algiers by Saidal’s CEO, Nabila Benygzer, Bioexpress Therapeutics’ CEO, Gerrit Hagens, and the Chairman of its Board, Luc Alain Savoy, the source added.

This agreement falls within the framework of strengthening international cooperation in the pharmaceutical and biotechnology sectors, with the primary aim of developing national skills and promoting a gradual technology transfer.

According to the communiqué, this collaboration seeks to create the conditions necessary for the local production of biotechnological products, thereby contributing to the enhancement of national capacities and the consolidation of health sovereignty.

Through this partnership, the Saidal group reaffirms its commitment to innovation, the development of national expertise, and the integration of cutting-edge technologies, while fostering ties with leading international partners, the communiqué concluded.